DIAGNOSTIC AND PROGNOSTIC INFORMATIVENESS OF THE DETECTION OF ASPERGILLUS GALACTOMANNAN ANTIGEN IN THE BLOOD SERUM OF ONCOHAEMATOLOGIC PATIENTS WITH INVASIVE ASPERGILLOSIS
Keywords:
oncohaematologic malignancies, invasive aspergillosis, galactomannan antigen.Abstract
Summary. Aim: to investigate diagnostic significance
and prognostic informativeness of the method of the
galactomannan antigen (GA) detection in blood serum of pediatric patients with haematologic malignancies for early diagnosis of invasive aspergillosis
(IA) and monitoring of antimicotic treatment efficacy. Objects and methods: 144 blood samples from
immunocompromised pediatric patients were investigated. 95% were patients with haematologic malignancies. All patients underwent standard laboratory testing procedures, which included microbiological methods and computer tomography studies aimed
at identifying the IA. Determination of the serum level of Aspergillus GA was performed using ELISA test
kits «Platelia Aspergillus Ag» (Bio-Rad) once a week
during the hospital stay and in the course of antimycotic therapy. Results: GA in the serum was detected
in 7 of 144 patients. The diagnosis of IA in patients
with present in the serum GA was confirmed by the results of computer tomographic study in 85.7% of cases. False negative results were absent. Number of false
positive results was 3%. One of the causes of false positive results may be drug cross-reactivity caused by the
treatment with piperacillin and tazobactam or its analogues. Conclusion: method of the detection of GA
serum level has high sensitivity and is quite informative methodical approach for early diagnosis of IA in
immunocompromised patients with haematologic malignancies as well as for the evaluation of the efficacy of antimycotic therapy.
References
Evans SE, Ost DE. Pneumonia in the neutropenic cancer
patient. Curr Opin Pulm Med 2015; 21 (3): 260–71.
Дягіль ІС, Мартіна ЗВ, Товстоган АО та ін. Інвазивний
аспергільоз у хворих на гостру мієлоїдну лейкемію. Клин
онкол 2013; 1 (9): 102–7.
Пересада ЛА. Инвазивный легочный аспергиллез —
случай из практики. Укр пульмонол журнал 2005; 1: 56–8.
Cadena J, Thompson GR 3rd, Patterson TF. Invasive asper
gillosis: current strategies for diagnosis and management. Infect
Dis Clin North Am 2016; 30 (1): 125–42.
Halpern AB, Lyman GH, Walsh TJ, et al. Primary antifun
gal prophylaxis during curative-intent therapy for acute myeloid
leukemia. Blood 2015; 126 (26): 2790–7.
Buchheidt D, Reinwald M, Spiess B, et al. Biomarker-based
diagnostic work-up of invasive pulmonary aspergillosis in immu
nocompromised paediatric patients — is Aspergillus PCR appro
priate? Mycoses 2016; 59 (2): 67–74.
Leeflang MM, Debets-Ossenkopp YJ, Wang J, et al. Galac
tomannan detection for invasive aspergillosis in immunocompro
mised patients. Cochrane Database Syst Rev 2015; 12: CD007394.
Ramos JT, Francisco L, Daoud Z, et al. Invasive fungal in
fections in children: similarities and differences with adults. Rev
Esp Quimioter 2016; 29 (Suppl 1): 59–65.
Gefen A, Zaidman I, Shachor-Meyouhas Y, et al. Serum ga
lactomannan screening for diagnosis of invasive pulmonary asper
gillosis in children after stem cell transplantation or with high-risk
leukemia. Pediatr Hematol Oncol 2015; 32 (2): 146–52.
Lehrnbecher T, Robinson PD, Fisher BT, et al. Galacto
mannan, Beta-D-Glucan and PCR-based assays for the diagno
sis of invasive fungal disease in pediatric cancer and hematopoiet
ic stem cell transplantation: a systematic review and meta-analy
sis. Clin Infect Dis 2016; pii: ciw592.
Obar JJ, Hohl TM, Cramer RA. New advances in invasive
aspergillosis immunobiology leading the way towards personalized
therapeutic approaches. Cytokine 2016; 84: 63–73.
De Pauw B, Walsh TJ, Donnelly P, et al. Revised definitions
of invasive fungal disease from the European Organization for Re
search and Treatment of Cancer/Invasive Fungal Infections Co
operative Group and the National Institute of Allergy and Infec
tious Diseases Mycoses Study Group (EORTC/MSG) Consensus
Group. Clin Infect Dis 2008; 46: 1813–21.
Hope W, Walsh T. Laboratory diagnosis of invasive asper
gillosis. Lancet Infect Dis 2005; 5: 609–22.
Hadrich I, Makni F, Cheikhrouhou F, et al. Clinical utili
ty and prognostic value of galactomannan in neutropenic patients
with invasive aspergillosis. Pathol Biol (Paris) 2012; 60 (6): 357–61.
Pechlivanoglou P, Le HH, Daenen S, et al. Mixed treat
ment comparison of prophylaxis against invasive fungal infec
tions in neutropenic patients receiving therapy for haematologi
cal malignancies: a systematic review. J Antimicrob Chemother
; 69 (1): 1–11.
